Please use this identifier to cite or link to this item:
Type: Artigo
Title: Low doses of 15d-PGJ2 induce osteoblast activity in a PPAR-gamma independent manner
Author: Napimoga, M. H.
Demasi, A. P. D.
Bossonaro, J. P.
de Araujo, V. C.
Clemente-Napimoga, J. T.
Martinez, E. F.
Abstract: Peroxisome proliferator-activated receptor-gamma (PPAR gamma) regulates both glucose metabolism and bone mass. Evidence suggests that the therapeutic modulation of PPAR gamma with synthetic agonists activity may elicit undesirable effects on bone. However, there is no information regarding its natural agonist 15d-PGJ(2), besides its excellent anti-inflammatory action. In the present study the effects of 15d-PGJ(2) on osteoblastic cells were determined. Osteoblastic cells (MC3T3) were cultured in an osteogenic medium in the presence of 1, 3 or 10 mu M of 15d-PGJ(2) during 21 days and alizarin and Von Kossa staining were employed. The protein expression (type-I collagen, osteonectin, osteopontin, RANKL, osteoprotegerin, HDAC-9c and PPAR-gamma) was evaluated after 3 days in the presence of 15d-PGJ(2) by western blotting and indirect immunofluorescence methods. The production of mineralized extracellular matrix was observed by transmission electron microscopy. After 72 h of culture, the mRNA was extracted for RT-qPCR analysis of RUNX expression. In the presence of all 3 tested 15d-PGJ2 doses, alizarin red and Von kossa staining were positive demonstrating the ability to the osteoblast differentiation. Type-I collagen and osteonectin proteins expression were up-regulated (p < 0.05) after 72 h in the presence of the smaller doses of 15d-PGJ(2). In contrast osteopontin, RANKL and OPG expression did not significantly alter. In the presence of 15d-PGJ(2) it was possible to visualize mineralized nodules in the extracellular matrix confirmed with the increased RUNX mRNA expression. 15d-PGJ(2) at small doses increased the osteoblast activity and the bone-related proteins expression
Subject: Inflamação
Osso e ossos
Country: Reino Unido
Editor: Elsevier
Citation: International Immunopharmacology. Elsevier Science Bv, v. 16, n. 2, n. 131, n. 138, 2013.
Rights: fechado
Identifier DOI: 10.1016/j.intimp.2013.03.035
Date Issue: 2013
Appears in Collections:FOP - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000320895400002.pdf2.38 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.